Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / CANCERRESEARCH     showing 1–6 of 6   RSS


for: Saturday, March 21, 2026



High Cancer Burden Shifted From Urban to Rural Areas and Gap Widening

cancer - Two American Cancer Society studies highlight increase in cancer burden in rural areas

AI Summary: Recent analyses show the colorectal cancer burden has moved increasingly from urban centers to rural areas, widening disparities. Researchers attribute the shift to screening shortfalls, limited access to specialty care and socioeconomic barriers, and call for targeted screening, resource reallocation and tailored prevention efforts as rural populations face rising incidence and poorer outcomes.


Clinical trials and treatment advances

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Early-onset, prevention, and genetics

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


Rural burden and access disparities

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / cancer


All Other Stories

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily



A blood test may tailor breast cancer treatment for older women

medicalxpress - For women age 70 and over with a common form of breast cancer, determining "the right size" of treatment can be challenging, in part because clinicians have limited tools to guide individualized treatment decisions. In a study published today in Clinical …

AI Summary: An ultra‑sensitive circulating tumor DNA assay shows promise in tailoring treatment for older breast cancer patients by detecting molecular signals that could guide therapy decisions and avoid unnecessary interventions. The blood test aims to refine risk stratification and personalize care where standard approaches often lack nuance, potentially sparing frail patients from overtreatment.


EBCC15: Less overtreatment through personalized radiotherapy and surveillance

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress


Liquid biopsies and sensors advancing cancer detection beyond breast

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


Other: biology and global burden stories

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


Ultrasensitive ctDNA: tailoring breast cancer care for older patients

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


All Other Stories

2 months / oncodaily

2 months / medicalxpress

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / nature



Vivek Subbiah: New Nature Study on Thymic Health and Response

oncodaily - Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn: “Wow published in NATURE journal ‘Thymic health and immunotherapy outcomes in patients […]

AI Summary: A new Nature study reveals that adult thymic health materially affects immune aging and responses to cancer treatment. Researchers show thymic integrity correlates with stronger immune surveillance and better therapy outcomes, reviving interest in thymus-targeted interventions. Experts describe the finding as a necessary reappraisal of an organ long written off by adult medicine — cue the applause.


Aging immunity: why older immune systems fail us

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress


Front lines: new targets and tactics in cancer immunotherapy

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / oncodaily

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress

2 months / medicalxpress


On the ground: adult thymus drives longevity and therapy success

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / medicalxpress


All Other Stories

2 months / oncodaily



TerraPower Isotopes Invests $450M in Actinium-225 Production Facility

oncodaily - TerraPower Isotopes (TPI), the Bill Gates-founded nuclear science company, unveiled plans on March 17, 2026 to invest $450 million in a state-of-the-art actinium-225 (Ac-225) manufacturing facility in Philadelphia’s Bellwether District. The 250,000-square…

AI Summary: TerraPower announced a $450 million investment to construct a commercial Actinium‑225 production facility to supply alpha‑emitting radioisotopes for targeted cancer therapies. The plan tackles chronic supply shortages, strengthens domestic radiopharmaceutical capacity and positions the company at the center of growing demand for targeted‑alpha therapeutics — and yes, investors are watching.

#healthcare #pharmaceuticals #biotech #drugdevelopment #oncology #healthcarefinance #cancerresearch #researchfunding #supplychain

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily

2 months / oncodaily


Back to Top / Saturday, March 21, 2026, 5:21 am / permalink 21091 / 5 stories in 2 months /

A liquid biopsy blood test may improve children's survival of cancer in Africa

medicalxpress - In a study published in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es Salaam, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt l…

AI Summary: A blood‑based liquid biopsy for EBV‑positive Burkitt’s lymphoma shows promise for earlier, less invasive diagnosis in endemic regions, potentially improving pediatric survival where tissue biopsies are scarce. Early data indicate actionable sensitivity and feasibility for low‑resource settings, offering a scalable path to faster treatment.

#healthcare #publichealth #biotech #medicaldevices #oncology #infectiousdisease #cancerresearch

2 months / medicalxpress


Back to Top / Saturday, March 21, 2026, 2:22 am / permalink 21087 / 2 stories in 2 months /

Rob Winn Appointed Director of NCI-Designated Fox Chase Cancer Center

oncodaily - Fox Chase Cancer Center shared a post on LinkedIn: “Temple Health – Temple University Health System today announced the appointment of Dr. Rob Winn, MD, as the next Cancer Center […]

AI Summary: Rob Winn has been appointed director of the NCI‑designated Fox Chase Cancer Center, taking the reins of clinical, research and strategic operations. His role will focus on strengthening translational research, patient care integration and institutional partnerships to advance the center's mission — you know, the usual: cure more cancer, argue less in committee meetings.

#healthcare #oncology #hospitaloperations #cancerresearch #researchfunding #clinicaltrials

2 months / oncodaily


Back to Top / Saturday, March 21, 2026, 1:21 am / permalink 21079 / 3 stories in 2 months /

Back to Top


CANCERRESEARCH Heatmap


90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS


You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Cybersecurity, Mergers and Acquisitions, Gene Therapy, Healthcare Finance and look for the RSS link.


NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.